2024 - PhD Neuroscience, University of Virginia
2008 - MSc Molecular and Cell Biology, University of California, Irvine
2005 - BSc Biochemistry, University of Virginia
Academic Background
Dr Van Deusen began her career investigating ion channel pharmacology and developing cell-based assays for drug discovery. Over the past 18 years, she has worked in the USA and UK developing novel pharmaceuticals, stem cell therapies, and research products. A decade of practical experience in academic and industrial settings has given Dr Van Deusen a strong background in scientific research, biomedical technologies, and professional publication. She is highly familiar with standardized scientific principles related to Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP), Good Tissue Practice (GTP) and Good Clinical Practice (GCP), and has worked with researchers, clinicians and industry partners from across the globe in preparing top-quality academic manuscripts, grant applications, marketing materials, regulatory documentation and websites. Her experience qualifies her to edit in fields related to biomedical technologies, biochemistry, molecular biology, cell biology, neuroscience, pharmacology, physiology, stem cell biology, and bioinformatics. Currently working as a post-doctoral researcher investigating neurodevelopmental disorders, Dr Van Deusen joined Edanz as an Editor in 2015.
Publishing History
Dr Van Deusen has authored more than a dozen peer-reviewed articles in high-impact journals such as Nature Neuroscience and Blood. She has presented research at several international conferences aimed at academic and industrial audiences.
Editing and Reviewing Experience
Dr Van Deusen has edited manuscripts for colleagues at institutions in the US and UK, assisted in the review of numerous manuscripts and textbook chapters, and completed advanced coursework in English composition.
Writing Experience
Dr Van Deusen has composed textbook chapters, marketing materials, and regulatory documentation describing development and commercialization of stem-cell¬–based therapies.
